标题
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C
作者
关键词
-
出版物
Expert Opinion on Drug Discovery
Volume 10, Issue 12, Pages 1363-1377
出版商
Informa Healthcare
发表日期
2015-11-13
DOI
10.1517/17460441.2015.1094051
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"
- (2015) G. J. Dore et al. CLINICAL INFECTIOUS DISEASES
- Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study
- (2015) Michael P. Curry et al. GASTROENTEROLOGY
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation
- (2015) Michael Charlton et al. GASTROENTEROLOGY
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
- (2015) Saleh A. Alqahtani et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- From non-A, non-B hepatitis to hepatitis C virus cure
- (2015) Jean-Michel Pawlotsky et al. JOURNAL OF HEPATOLOGY
- Hepatitis C
- (2015) Daniel P Webster et al. LANCET
- A pill a day keeps HCV away
- (2015) Ivan Gentile et al. LANCET INFECTIOUS DISEASES
- New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US
- (2015) M. McCarthy BMJ-British Medical Journal
- New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US
- (2015) M. McCarthy BMJ-British Medical Journal
- Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
- (2015) Alena M. Pfeil et al. PLoS One
- Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection
- (2014) R. S. Koff ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938
- (2014) Jeremie Guedj et al. ANTIVIRAL THERAPY
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies
- (2014) Imran Shahid et al. CRITICAL REVIEWS IN MICROBIOLOGY
- Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency
- (2014) Floriano Rosina et al. DIGESTIVE AND LIVER DISEASE
- The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
- (2014) Gisa Gerold et al. DIGESTIVE DISEASES
- Sofosbuvir: First Global Approval
- (2014) Gillian M. Keating et al. DRUGS
- Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection
- (2014) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
- (2014) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C
- (2014) Guido Stirnimann EXPERT OPINION ON PHARMACOTHERAPY
- Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
- (2014) Ivan Gentile et al. Expert Review of Anti-Infective Therapy
- New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
- (2014) Jean–Michel Pawlotsky GASTROENTEROLOGY
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- Global distribution and prevalence of hepatitis C virus genotypes
- (2014) Jane P. Messina et al. HEPATOLOGY
- Treatment of Hepatitis C
- (2014) Anita Kohli et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
- (2014) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Global epidemiology and genotype distribution of the hepatitis C virus infection
- (2014) Erin Gower et al. JOURNAL OF HEPATOLOGY
- A General and Enantioselective Approach to Pentoses: A Rapid Synthesis of PSI-6130, the Nucleoside Core of Sofosbuvir
- (2014) Manuel Peifer et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program
- (2014) S. Bruno et al. JOURNAL OF VIRAL HEPATITIS
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C treatment: an incipient therapeutic revolution
- (2014) Andrew S. deLemos et al. TRENDS IN MOLECULAR MEDICINE
- A Novel Promising Therapeutic Option Against Hepatitis C Virus: An Oral Nucleotide NS5B Polymerase Inhibitor Sofosbuvir
- (2013) I. Gentile et al. CURRENT MEDICINAL CHEMISTRY
- Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
- (2013) N. Coppola et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
- (2013) David Alan Herbst et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature
- (2013) Ferdinando Fusco et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hepatitis C therapy with HCV NS5B polymerase inhibitors
- (2013) Vincent Soriano et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
- (2013) Maribel Rodríguez-Torres Expert Review of Anti-Infective Therapy
- A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C
- (2013) Ivan Gentile et al. Hepatitis Monthly
- Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource
- (2013) Donald B. Smith et al. HEPATOLOGY
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics
- (2013) Anuoluwapo Osinusi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
- (2013) Kris V Kowdley et al. LANCET
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- Epidemiology and natural history of HCV infection
- (2013) Behzad Hajarizadeh et al. Nature Reviews Gastroenterology & Hepatology
- The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
- (2013) Ralf Bartenschlager et al. NATURE REVIEWS MICROBIOLOGY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sustained virological response: A milestone in the treatment of chronic hepatitis C
- (2013) Filomena Morisco WORLD JOURNAL OF GASTROENTEROLOGY
- Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
- (2013) Catherine Stedman Therapeutic Advances in Gastroenterology
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection
- (2012) Eric Lawitz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects
- (2012) Jill Denning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs
- (2012) Karolina Madela et al. Future Medicinal Chemistry
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
- (2012) Maribel Rodriguez-Torres et al. JOURNAL OF HEPATOLOGY
- Hepatitis C virus—host interactions, replication, and viral assembly
- (2012) Ana Shulla et al. Current Opinion in Virology
- A New Evolutionary Model for Hepatitis C Virus Chronic Infection
- (2012) Rebecca R. Gray et al. PLoS Pathogens
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2011) JOURNAL OF HEPATOLOGY
- New direct-acting antivirals' combination for the treatment of chronic hepatitis C
- (2011) Tarik Asselah et al. LIVER INTERNATIONAL
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PSI-7851, a Pronucleotide of -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication
- (2010) A. M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
- (2010) Alexander J. Thompson et al. GASTROENTEROLOGY
- Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977
- (2010) Eisuke Murakami et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
- (2010) Ivan Gentile et al. JOURNAL OF HEPATOLOGY
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus
- (2010) Michael J. Sofia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
- (2010) Tarik Asselah et al. LIVER INTERNATIONAL
- Assembly of infectious hepatitis C virus particles
- (2010) Ralf Bartenschlager et al. TRENDS IN MICROBIOLOGY
- The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus
- (2009) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial
- (2009) Ivan Gentile et al. JOURNAL OF CLINICAL APHERESIS
- An Efficient and Diastereoselective Synthesis of PSI-6130: A Clinically Efficacious Inhibitor of HCV NS5B Polymerase
- (2009) Peiyuan Wang et al. JOURNAL OF ORGANIC CHEMISTRY
- The global burden of hepatitis C
- (2009) Daniel Lavanchy LIVER INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More